Patent US3398700A successfully refreshed from Google Patents.
Patent US5234940A successfully refreshed from Google Patents.
US5234940A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Photochemotherapeutic method using 5-aminolevulinic acid and precursors thereof
Assignee: Queen's University
•
Filing: 1992-04-08
•
Granted: 1993-08-10
•
Expires: 2012-04-08
Abstract
Abstract A method of detecting and treating malignant and non-malignant tissue abnormalities and lesions of the skin; conjunctiva; respiratory, digestive and vaginal mucosa; endometrium and urothelium; and for ablating the endometrial tissue and treating body fluids containing suspended abnormal cells, and for treating cancers of the nervous system in which 5-aminolevulinic acid or precursor thereof is administered to the patient in an amount sufficient to induce synthesis fluorescence and/or photosensitizing concentrations of of protoporphyrin IX in the abnormal cells, followed by exposure of the abnormal cells to light of photoactivating wavelengths.
Inventors
- 👤 James C. Kennedy
- 👤 Roy H. Pottier
- 👤 Robert L. Reid
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 14:51
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/185; A61K31/19; A61K31/195; A61K31/33; A61K31/555; A61K41/00; A61K41/0057; A61K41/0061
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
63 words
A method for creating malignant and non-malignant cellular abnormalities of the endometrium and gonads in a patient comprising administering to said patient an effective amount of a precursor of protoporphyrin IX in the biosynthetic pathway for heme so as to induce synthesis of protoporphyrin IX in said abnormalities, and exposing said abnormalities to light within the photoactivating action spectrum of said protoporphyrin IX.
Claim 2
Independent Claim
63 words
A method for creating malignant and non-malignant cellular abnormalities of the endometrium and gonads in a patient comprising administering to said patient an effective amount of a precursor of protoporphyrin IX in the biosynthetic pathway for heme so as to induce synthesis of protoporphyrin IX in said abnormalities, and exposing said abnormalities to light within the photoactivating action spectrum of said protoporphyrin IX.
Claim 3
Dependent Claim
20 words
A method as claimed in claim 1 wherein said precursor of protoporphyrin IX is 5-aminolevulinic acid or a precursor thereof.
Claim 4
Independent Claim
63 words
A method for treating dysfunctional uterine bleeding, endometriosis, iron deficiency anemia caused by excessive menstrual bleeding in a patient comprising administering to said patient a precursor of protoporphyrin IX in the biosynthetic pathway for heme, so as to induce synthesis of protoporphyrin IX in endometrial tissues in said patient, and exposing said tissues to light within the photoactivating spectrum of said protoporphyrin IX.
Claim 5
Independent Claim
63 words
A method for treating dysfunctional uterine bleeding, endometriosis, iron deficiency anemia caused by excessive menstrual bleeding in a patient comprising administering to said patient a precursor of protoporphyrin IX in the biosynthetic pathway for heme, so as to induce synthesis of protoporphyrin IX in endometrial tissues in said patient, and exposing said tissues to light within the photoactivating spectrum of said protoporphyrin IX.
Claim 6
Independent Claim
50 words
A method for sterilizing a patient comprising administering to said patient a precursor of protoporphyrin IX in the biosynthetic pathway for heme, so as to induce synthesis of protoporphyrin IX in endometrial tissues in said patient, and exposing said tissues to light within the photoactivating spectrum of said protoporphyrin IX.
Claim 7
Independent Claim
50 words
A method for sterilizing a patient comprising administering to said patient a precursor of protoporphyrin IX in the biosynthetic pathway for heme, so as to induce synthesis of protoporphyrin IX in endometrial tissues in said patient, and exposing said tissues to light within the photoactivating spectrum of said protoporphyrin IX.
Claim 8
Dependent Claim
50 words
A contraceptive method for female patients comprising administering to said patient a precursor of protoporphyrin IX in the biosynthetic pathway for heme, so as to induce synthesis of protoporphyrin IX in endometrial tissues in said patient, and exposing said tissues to light within the photoactivating spectrum of said protoporphyrin IX.
Claim 9
Dependent Claim
50 words
A contraceptive method for female patients comprising administering to said patient a precursor of protoporphyrin IX in the biosynthetic pathway for heme, so as to induce synthesis of protoporphyrin IX in endometrial tissues in said patient, and exposing said tissues to light within the photoactivating spectrum of said protoporphyrin IX.
Claim 10
Dependent Claim
16 words
A method as claimed in claim 3 wherein said precursor is 5-aminolevulinic acid or precursor thereof.
Claim 11
Dependent Claim
16 words
A method as claimed in claim 4 wherein said precursor is 5-aminolevulinic acid or precursor thereof.
Claim 12
Dependent Claim
16 words
A method as claimed in claim 5 wherein said precursor is 5-aminolevulinic acid or precursor thereof.
References Cited (Backward Citations)
US3846490A
Cited
US3934369A
Cited
US3973129A
Cited
US5043101A
Cited
US4977177A
Cited
EP0233701A2
Cited
US4772681A
Cited
JPS62205081A
Cited
JPS6263586A
Cited
US5004811A
Cited
US4997639A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-08-09 | 1997-02-08 | 1997-08-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-08-09 | 2001-02-08 | 2001-08-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-08-09 | 2005-02-08 | 2005-08-10 | $7700.00 | Window Closed / Lapsed |